Abl Bio Stock EBITDA
| 298380 Stock | KRW 24,800 450.00 1.78% |
ABL Bio fundamentals help investors to digest information that contributes to ABL Bio's financial success or failures. It also enables traders to predict the movement of ABL Stock. The fundamental analysis module provides a way to measure ABL Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ABL Bio stock.
ABL |
ABL Bio Company EBITDA Analysis
ABL Bio's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current ABL Bio EBITDA | (53.58 B) |
Most of ABL Bio's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ABL Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, ABL Bio reported earnings before interest,tax, depreciation and amortization of (53.58 Billion). This is 6205.91% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The ebitda for all Republic of Korea stocks is significantly higher than that of the company.
Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
ABL Fundamentals
| Return On Equity | 5.6 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (6.16) % | |||
| Current Valuation | 866.33 B | |||
| Shares Outstanding | 45.3 M | |||
| Shares Owned By Insiders | 31.53 % | |||
| Shares Owned By Institutions | 12.89 % | |||
| Price To Sales | 101.38 X | |||
| Revenue | 5.33 B | |||
| Gross Profit | 8.06 B | |||
| EBITDA | (53.58 B) | |||
| Net Income | (43.56 B) | |||
| Cash And Equivalents | 21.59 B | |||
| Total Debt | 72.32 M | |||
| Debt To Equity | 1.40 % | |||
| Current Ratio | 14.71 X | |||
| Cash Flow From Operations | (40.61 B) | |||
| Beta | 1.08 | |||
| Market Capitalization | 958.17 B | |||
| Total Asset | 65.45 B | |||
| Net Asset | 65.45 B |
About ABL Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABL Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABL Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABL Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABL Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the ABL Bio information on this page should be used as a complementary analysis to other ABL Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for ABL Stock analysis
When running ABL Bio's price analysis, check to measure ABL Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABL Bio is operating at the current time. Most of ABL Bio's value examination focuses on studying past and present price action to predict the probability of ABL Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABL Bio's price. Additionally, you may evaluate how the addition of ABL Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |